Myomo

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. It offers MyoPro, an upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myomo reports 9% revenue growth in Q1 2024 earnings call

Myomo's Q1 2024 performance reflects revenue growth driven by favorable CMS developments, with plans to double manufacturing capacity and achieve cash flow breakeven by Q4 2024.
The company's strategic strengths lie in its focus on the prevalence group, international expansion, and commitment to market leadership through increased output and R&D investments.
Challenges include managing operating expenses, scaling manufacturing capacity, and meeting revenue targets amidst market competition and reimbursement rate fluctuations.
Opportunities abound in international growth, market expansion in Germany, and the potential for accelerated U.S. revenue, supported by investments in resources and R&D.

Myomo excels in Q2 with record revenues and global expansion

Myomo's Q2 2024 performance reflects strong revenue growth, operational efficiency gains, and strategic expansion initiatives.
The company's strengths lie in international revenue generation, production facility expansion plans, and commitment to meeting product demand.
Challenges include scaling production while ensuring quality, monitoring advertising ROI, and balancing R&D with operational needs.
Opportunities arise from investor engagement, increased advertising, and continued innovation to drive market presence and revenue growth.

Myomo reports record Q3 revenue, eyes global expansion and market partnerships

Myomo's Q3 performance showcased robust revenue growth, pipeline expansion, and strategic partnerships, positioning the company for sustained success and global expansion.
While facing operational losses, Myomo's strengths in product innovation, market expansion, and capacity planning provide a solid foundation for future growth and profitability.
Challenges in cost management, market penetration, and regulatory compliance need to be addressed, but the company's proactive approach to expansion and partnerships bodes well for seizing growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The firm is also involved in selling products through various other sales channels including through orthotics and prosthetics providers, veterans’ administration, and to distributors in certain accounts and geographic markets. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.

Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that its request to the Centers for Medicare and Medicaid Services (“CMS”) to classify the Company's MyoPro as a brace has been published for public comment. Currently the MyoPro is assigned Healthcare Common Procedure Coding System (“HCPCS”) billing codes.

Centers for Medicare and Medicaid Services Accepts Myomo's Application to Classify the MyoPro® as a Brace

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will be participating in the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday June 20, 2023. Paul Gudonis, Myomo's chairman and chief executive officer, and David Henry, Myomo's chief financial officer, will be participa.

Myomo To Participate in the Maxim Group Virtual Healthcare Conference Hosted by M-Vest

Myomo, Inc. (MYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Myomo, Inc. (MYO) Is a Great 'Buy the Bottom' Stock Now

Myomo, Inc. (NYSE:MYO ) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Scott Henry - ROTH Capital Jim Sidoti - Sidoti & Company Edward Woo - Ascendant Capital Operator Good afternoon, and welcome to the Myomo First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.

Myomo, Inc (MYO) Q1 2023 Earnings Call Transcript

Myomo, Inc. (MYO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.41 per share a year ago.

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2023. Financial and operational highlights for the first quarter of 2023 include the following: Product revenue was $3.4 million, up 20% compared with the prior year quarter. Total revenue decreas.

Myomo Reports First Quarter 2023 Financial Results Featuring 20% Year Over Year Increase in Product Revenue

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2023 on May 10, 2023. The Company will host a conference call the same day, Wednesday, May 10, 2023 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief.

Myomo to Report First Quarter Financial Results on May 10, 2023

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces receipt of the final portion of the initial license fee under the Technology License Agreement with its joint venture company in China, Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the “JV Company”).

Myomo Receives Technology License Fee Payment from China Joint Venture Company

Myomo Makes NYSE American Section 610(b) Public Announcement

Myomo, Inc (NYSE:MYO ) Q4 2022 Earnings Conference Call March 13, 2023 10:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Edward Woo - Ascendiant Capital Ben Haynor - Alliance Global Partners Jeremy Pearlman - Maxim Group Operator Good morning, and welcome to the Myomo, Inc. Fourth Quarter and Full Year 2022 Earnings Conference Call. All participants will be in listen-only mode.

Myomo, Inc (MYO) Q4 2022 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022. Financial and operational highlights for the fourth quarter of 2022 include the following: Product and total revenues were $4.

Myomo Reports Fourth Quarter and Full Year 2022 Financial Results

Adial Pharmaceuticals Inc

Akebia Therapeutics

Asensus Surgical

Borqs Technologies

Blue Star Foods Corp

Kiromic Biopharma

Novo Integrated Sciences, Inc.

Sono Group NV

vTv Therapeutics

Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Hot Penny Stocks Under $1 To Watch This Week

Penny stocks under $1 to watch this week. The post 7 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1 To Watch This Week

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2022 on March 13, 2023 before the opening of the market. The Company will host a conference call the same day, Monday, March 13, 2023 at 10:00 a.m.

Myomo to Report Fourth Quarter Financial Results on March 13, 2023

Myomo to Report Third Quarter Financial Results on March 13, 2023

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will presenting at the 35th Annual Roth Conference, March 13-14, 2023 at The Ritz-Carlton, Dana Point, Calif. David Henry, Myomo's chief financial officer will participate in a “Fireside Chat” on Monday, March 13th at 1:30 p.m.

Myomo To Participate in the 35th Annual Roth Conference

Finding the best penny stocks to buy seems easy.

Best Penny Stocks To Buy Under $1? 4 To Watch Now

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that for the first time, the National Disability Insurance Scheme (NDIS) in Australia approved a MyoPro for a patient with a paralyzed arm. The NDIS aids over 500,000 Australians with disabilities through reimbursement for necessary services and support.

MyoPro Approved in Australia by National Disability Insurance Scheme

Elys Game Technology, Corp.

Gossamer Bio Inc

Kala Pharmaceuticals

Oric Pharmaceuticals

Soleno Therapeutics

Sitio Royalties Corp

While everyone knows that in order to have a market, there must be bulls and bears, that's not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position.

7 Top Short-Squeeze Candidates to Watch in February

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors.

Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

Clear Channel Outdoor Holdings

Werewolf Therapeutics

Tenaya Therapeutic

Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy In January According To Insiders

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses.

Myomo Announces Closing of $6.5 Million Upsized Public Offering

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses.

Myomo Announces Pricing of $6.5 Million Upsized Public Offering

BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a reduction in force for the purpose of improving operating efficiency in its direct billing channel and reduce its cash burn. The action today involved the elimination of approximately 12% of its workforce, impacting employees in its call center and administrative functions. This action and other cost reductions being undertaken by the Company are expected to save in excess of $2 million on an annual basis.

News for Myomo Stock (MYO)